Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Pharmacol Ther ; 95(6): 601-7, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24509430

RESUMO

Hyperpolarization-activated, cyclic nucleotide-gated 4 (HCN4) channels comprise the final pathway for autonomic heart rate (HR) regulation. We hypothesized that HCN4 inhibition could reverse autonomic imbalance in a human model of cardiac sympathetic activation. Nineteen healthy men ingested oral metoprolol+reboxetine, ivabradine+reboxetine, or placebo+reboxetine in a double-blind, randomized, crossover fashion. We assessed HR, blood pressure (BP), stroke volume, and cardiac output during rest and profound orthostatic stress. HR variability, BP variability, and baroreflex sensitivity were analyzed. Metoprolol, but not ivabradine, decreased resting HR and BP. Ivabradine attenuated the HR increase to orthostatic stress, albeit to a lesser extent than metoprolol. Stroke volume and cardiac output at a given HR were significantly lower with metoprolol. Unlike metoprolol, ivabradine did not affect HR variability, BP variability, or baroreflex sensitivity. Ivabradine attenuates sympathetic influences on HR at the sinus node level, leaving myocardial sympathetic activation unopposed. Reversal of parasympathetic dysfunction by ivabradine appears limited.


Assuntos
Coração/fisiologia , Marca-Passo Artificial , Sistema Nervoso Simpático/fisiologia , Adolescente , Inibidores da Captação Adrenérgica/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Adulto , Benzazepinas/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Cardiotônicos/farmacologia , Estudos Cross-Over , Método Duplo-Cego , Determinação de Ponto Final , Frequência Cardíaca/efeitos dos fármacos , Humanos , Canais Disparados por Nucleotídeos Cíclicos Ativados por Hiperpolarização/antagonistas & inibidores , Ivabradina , Masculino , Metoprolol/farmacologia , Morfolinas/farmacologia , Proteínas Musculares/antagonistas & inibidores , Norepinefrina/metabolismo , Intolerância Ortostática/fisiopatologia , Canais de Potássio , Reboxetina , Volume Sistólico/efeitos dos fármacos , Síncope/fisiopatologia , Adulto Jovem
2.
Placenta ; 34(11): 983-9, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24008071

RESUMO

INTRODUCTION: Maternal obesity (MO) remains a serious obstetric problem with acute and chronic morbidities for both mothers and offspring. The mechanisms underlying these adverse consequences of MO remain unknown. Endocannabinoids (ECB) are neuromodulatory lipids released from adipocytes and other tissues. Metabolic crosstalk between placenta and adipocytes may mediate sequelae of MO. The goal of this study was to elucidate placental and systemic ECB in MO. MATERIAL AND METHODS: Placentas, sera, and subcutaneous fat were collected at Cesarean sections performed near term (0.9 G) in four non-obese (nOB) and four obese (OB) baboons (Papio spp.). Concentrations of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured by liquid chromatography coupled to tandem mass spectrometry. AEA and 2-AG pathways were characterized in placentas by Q-RT-PCR, Western blot and immunohistochemistry. RESULTS: Placental 2-AG levels were lower and maternal fat AEA levels were higher in OB (1254.1 ± 401.3 nmol/kg and 17.3 ± 4 nmol/kg) vs. nOB (3124.2 ± 557.3 nmol/kg and 3.1 ± 0.6 nmol/kg) animals. Concentrations of 2-AG correlated positively between maternal fat and placenta (r = 0.82, p = 0.013), but correlated negatively with maternal leptin concentrations (r = -0.72, p = 0.04 and r = -0.83, p = 0.01, respectively). CONCLUSION: This is the first study to demonstrate differential ECB pathway regulation in maternal fat and placenta in MO. Differential regulation and function exist for AEA and 2-AG as the major ECB pathways in placenta.


Assuntos
Modelos Animais de Doenças , Endocanabinoides/metabolismo , Obesidade/metabolismo , Placenta/metabolismo , Complicações na Gravidez/metabolismo , Receptores de Canabinoides/metabolismo , Gordura Subcutânea Abdominal/metabolismo , Animais , Ácidos Araquidônicos/sangue , Ácidos Araquidônicos/metabolismo , Transporte Biológico , Cromatografia Líquida de Alta Pressão , Endocanabinoides/sangue , Feminino , Regulação da Expressão Gênica no Desenvolvimento , Glicerídeos/sangue , Glicerídeos/metabolismo , Leptina/sangue , Obesidade/sangue , Obesidade/patologia , Papio , Placenta/patologia , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/metabolismo , Gravidez , Complicações na Gravidez/sangue , Complicações na Gravidez/patologia , Receptor CB1 de Canabinoide/genética , Receptor CB1 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/biossíntese , Receptor CB2 de Canabinoide/genética , Receptor CB2 de Canabinoide/metabolismo , Receptores de Canabinoides/biossíntese , Receptores de Canabinoides/genética , Gordura Subcutânea Abdominal/patologia , Espectrometria de Massas em Tandem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA